Geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD), is a leading cause of visual impairment and blindness in the United States and Europe. Degradation of cells…
The wet age-related macular degeneration (AMD) therapy market has long been dominated by three vascular endothelial growth factor (VEGF) inhibitors: Roche / Genentech / Chugai’s Avastin, Roche /…
The age-related macular degeneration (AMD) market in the United States is unique given that market penetration of approved branded therapies—Roche / Genentech’s Lucentis, Regeneron’s Eylea,…
Wet age-related macular degeneration (also known as exudative or neovascular AMD) is characterized by leakage from newly formed blood vessels, distorting the surface of the retina and causing…
The wet age-related macular degeneration (AMD) therapy market has long been dominated by three VEGF inhibitors: Roche / Genentech / Chugai’s Avastin, Roche / Genentech / Novartis’s Lucentis,…
Three anti-VEGF therapies have long been mainstays of treatment in wet age-related macular degeneration (AMD)—Roche / Genentech’s Lucentis, Regeneron’s Eylea, and Roche / Genentech’s…
The wet age-related macular degeneration (AMD) therapy market in the United States is unique given that the key approved therapies—Roche / Genentech’s Lucentis, Regeneron’s Eylea, Novartis’…
The wet age-related macular degeneration (AMD) therapy market in the United States is unique given that the key approved therapies—Roche / Genentech’s Lucentis, Regeneron’s Eylea, Novartis’…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key AMD patient populations covering 171 countries and more than 99% of…
Clarivate Epidemiology’s coverage of age-related macular degeneration (AMD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…
Clarivate Epidemiology’s coverage of age-related macular degeneration (AMD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…
Clarivate Epidemiology’s coverage of age-related macular degeneration (AMD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…
Clarivate Epidemiology’s coverage of age-related macular degeneration (AMD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…
Clarivate Epidemiology’s coverage of age-related macular degeneration (AMD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…
Clarivate Epidemiology’s coverage of age-related macular degeneration (AMD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…